CS
CRVS icon

Credit Suisse’s Corvus Pharmaceuticals CRVS Stock Holding History

Credit Suisse’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,593
Closed -$194K – 3884
2018
Q3 		$194K Buy
+22,593
New +$226K ﹤0.01% 3660
2016
Q2 		– Sell
-188,979
Closed -$2.74M – 4211
2016
Q1 		$2.74M Buy
+188,979
New +$2.71M ﹤0.01% 1976

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Credit Suisse's CRVS Position: Q4 2018 in Review

Credit Suisse sold out of Corvus Pharmaceuticals (CRVS) in Q4 2018, closing a stake of 22,593 shares — an estimated $194K sold.

Credit Suisse first reported a position in CRVS in Q1 2016 and held it in 2 quarters. The position peaked at $2.74M in Q1 2016. 61 funds tracked by Wall St. Rank hold CRVS as of Q4 2018.

  • Credit Suisse reported no remaining Corvus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Credit Suisse sold 22,593 Corvus Pharmaceuticals shares in Q4 2018, an estimated $194K.
  • Credit Suisse first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Credit Suisse's Corvus Pharmaceuticals position peaked at $2.74M in Q1 2016.
  • 61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2018.

Based on Credit Suisse's 13F filing for Q4 2018, filed 13 Feb 2019.